Australian PBS cost set to fall 4.7%

25 June 2006

Australia's annual A$6.0 billion ($4.5 billion) cost of the Pharmaceutical Benefits Scheme will fall 4.7%, or A$260.0 million in the coming financial year due to an ongoing reduction in the numbers of prescriptions that patients are filling. The reduction in 2006-7 is anticipated due to lower-than-expected growth in certain drugs, such as entire classes of medicines used to lower cholesterol and treat mental disorders.

PBS figures last year showed a slowdown in prescriptions after the federal government increased co-payment (the amount patients pay for medicines at pharmacies) about 20% from January 1, 2005. Last year, the government also increased the number of prescriptions that patients need to fill each year before they become eligible under the PBS safety net scheme. This caps the total annual amount a patient pays, and any further amount is paid by the PBS.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight